Clinical Trial Update: An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial evaluating camrelizumab plus apatinib mesylate for advanced gastrointestinal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Harbin Medical University | Conditions: Gastrointestinal Cancer, Immunotherapy | Phase 2 | Status: UNKNOWN